Form 8-K - Current report:
SEC Accession No. 0001640334-25-001030
Filing Date
2025-06-12
Accepted
2025-06-12 16:20:34
Documents
14
Period of Report
2025-05-14
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K lxrp_8k.htm   iXBRL 8-K 25383
  Complete submission text file 0001640334-25-001030.txt   157183

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20250514.xsd EX-101.SCH 6275
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20250514_lab.xml EX-101.LAB 16213
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20250514_cal.xml EX-101.CAL 898
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20250514_pre.xml EX-101.PRE 11893
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20250514_def.xml EX-101.DEF 4149
16 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_8k_htm.xml XML 5583
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 8-K | Act: 34 | File No.: 001-39874 | Film No.: 251042958
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)